TriAgenics, Inc., pioneer of Zero3 TBA, a fully guided tooth bud ablation system designed to prevent third molar formation, announced that David Thrower has been named president and CEO.
Thrower has held numerous executive leadership positions at the intersection of consumer and medical device markets. His previous roles include VP of Global Marketing at Align Technology, the makers of Invisalign orthodontic aligners. During his tenure, the company grew from early revenues to approximately $200 million in sales. Among other roles, David served as CEO for hearing aid developer InSound Medical, which was acquired by Sonova Holdings AG, and was CEO at venture-backed Asante Solutions, where he successfully guided a novel insulin pump through FDA clearance and early commercial launch.
“I’m honored to join TriAgenics at this pivotal moment, as the FDA begins its review of our clinical submission,” said Thrower. “For decades, wisdom tooth removal has been a painful and disruptive experience—often involving anesthesia, significant swelling, and days of missed school and work for patients and parents. Preclinical animal studies indicate that TriAgenics’ Zero3 TBA technology has the potential to dramatically reduce, or even eliminate, the pain and complications typically associated with this common procedure.”
Thrower began his career as a strategy consultant at Bain & Company. He earned an MBA from Harvard Business School and received a BS in Mathematical and Computational Sciences from Stanford University. Thrower joined TriAgenics’ board of directors in 2020.
Leigh Colby, TriAgenics co-founder and former CEO, will now serve as chief clinical officer.
“David brings invaluable expertise in market strategy and commercial execution. As a key architect of Align’s global aligner strategy and adoption plan, David played a pivotal role in their early commercial success,” Colby said. “Having served on TriAgenics’ board for the past five years, David is deeply familiar with our operations and well-positioned to help drive our commercial launch and next phase of growth.”
About TriAgenics
TriAgenics is a disruptive oral health care company that has pioneered the development of a one-minute treatment designed to prevent third molars from ever forming. Based on extensive animal trials, TriAgenics’ Zero3 TBA system is expected to eliminate the pain and complications normally associated with third molar extraction. The Zero3 TBA system is currently pending FDA clearance. TriAgenics’ mission is to provide dentists and their patients with a non-surgical alternative that has no painful recovery or need to miss work or school.
For more information, please visit www.triagenics.com.
FEATURED IMAGE CREDIT: Stockwerk-fotodesign/Shutterstock.com.
